ORGANOGENESIS 2024 Q4
Earnings Overview & AI Insights

Earnings Performance

Summary of Financial Performance:

Organogenesis Holdings reported strong Q4 fiscal year 2024 performance, achieving 27% year-over-year revenue growth, exceeding the high end of guidance provided in the prior quarter. The revenue outperformance was attributed to robust customer demand and less disruption from delayed implementation of the Local Coverage Determinations (LCDs) ruling by Medicare Administrative Contractors (MACs). The company highlighted strong execution in navigating this regulatory environment and driving momentum in its core business.

Company Outlook & Strategy:

Management provided 2025 financial guidance and emphasized its continued advocacy for value-based payment methodologies for skin substitute products. The proposed transition to a fixed per square centimeter reimbursement model is expected to reduce Medicare Part B costs, improve patient access, and enhance treatment outcomes. The company remains committed to engaging with CMS to drive these changes and position itself as a leader in the market for skin substitute products.

Key Industry Trends:

Organogenesis acknowledged ongoing reforms in the skin substitute market, with the finalized LCDs representing a key regulatory milestone. The company supports evidence-based approaches that prioritize clinical efficacy and real-world data, viewing these changes as a step toward cleaning up the market and ensuring fair access to products. Broader industry trends include increased focus on cost efficiency and ### Summary of Financial Performance: Organogenesis Holdings reported Q4 fiscal year 2024 revenue growth of 27%, exceeding the high end of its guidance. This strong performance was attributed to robust underlying business trends and customer demand, particularly in the latter half of the quarter, driven by less disruption from the delayed effective date of the final LCD ruling. The company highlighted its focus on maintaining access to high-quality care and pushing for reforms in payment methodologies.

Company Outlook & Strategy:

The company introduced its 2025 financial guidance, emphasizing continued advocacy for value-based payment methodologies for skin substitute products. Organogenesis is focused on reforms that could reduce Medicare Part B expenditures, improve patient access, and provide physicians with flexibility to deliver patient-specific treatments. The management remains proactive in working with CMS and MACs to drive policy changes while maintaining a strong strategic focus on customer engagement and product innovation.

Key Industry Trends:

• The final LCD ruling by MACs, with an effective date of February 12, 2025, is seen as a major regulatory shift in the skin substitute product market.
• Organogenesis noted a broader industry move toward evidence-based coverage decisions, which aligns with its long-term advocacy for reforms.
• A push for **value-based payment ### Summary of Financial Performance: Organogenesis Holdings reported Q4 FY2024 revenue growth of 27%, exceeding the high end of its guidance range. This strong performance was attributed to robust customer demand and favorable business trends. The delay in the effective date for the final LCD (Local Coverage Determination) ruling by MACs (Medicare Administrative Contractors) to February 12, 2025, resulted in less market disruption, positively impacting sales. Management highlighted the company’s continued advocacy for value-based payment reforms to optimize Medicare Part B expenditures and improve patient outcomes.

Company Outlook & Strategy:

Organogenesis introduced its FY2025 financial guidance, with the details to be elaborated by the CFO. The company remains focused on regulatory advocacy, particularly with CMS (Centers for Medicare & Medicaid Services), pushing for value-based payment systems for skin substitutes. This strategy is seen as a key driver for long-term cost savings, improved patient access, and better clinical outcomes. Management emphasized its commitment to maintaining market leadership and engaging with regulators to shape industry reforms.

Key Industry Trends:

The company acknowledged the finalization of LCD policies for skin substitute products as a positive step toward marketplace reform, emphasizing the importance of evidence-based coverage (clinical and real Summary of Financial Performance:
Organogenesis Holdings reported a strong Q4 performance with revenue growth of 27%, exceeding the high end of prior guidance. The results were driven by robust underlying business trends and higher-than-expected customer demand. The delayed effective date of the finalized LCD ruling (to February 12, 2025) contributed to reduced marketplace disruption, which positively impacted sales. The company emphasized its initiatives in advocating for value-based payment methodologies to improve Medicare efficiency and patient outcomes.

Company Outlook & Strategy:
For fiscal 2025, Organogenesis introduced financial guidance, emphasizing its ongoing commitment to value-based payment reforms for skin substitute products. The company continues to engage with CMS to advocate for payment policy changes aimed at reducing Medicare Part B expenditures and improving patient access. Management remains optimistic about capitalizing on the finalized LCDs as a favorable step toward market reform.

Key Industry Trends:
The finalized LCDs represent a significant regulatory shift in the skin substitutes industry, prioritizing clinical efficacy. Organogenesis sees this as an opportunity to clean up the marketplace and improve access and outcomes for patients. The delayed effective date of the LCD ruling has temporarily mitigated market disruption, allowing for stronger demand in the near term.

Operational Highlights: